DIABETIC FOOT INFECTIONS AND THEIR MANAGEMENT IN A TERTIARY CARE HOSPITAL
AbstractBackground: Diabetic foot is a common complication of diabetes world over. We conducted this studyto determine common microbiological pathogens in Diabetic Foot Infections (DFI) at a tertiary carehospital and their management. Methods: In this observational study deep wound swabs of all admitteddiabetic patients were taken, pathogens isolated, antibiotic used and its response depending on completeresolution of symptoms and biochemical markers were recorded. Data were analysed on SPSS-11.Results: A total of 114 cases were recorded. Sixty-eight (59%) cases had ulcers on forefoot, 28 (25%)mid-foot and 18 (16%) hind-foot. One hundred and four pathogens were isolated from wound swabsafter debridement. Commonest pathogen isolated was Staphylococcus aureus (52, 46%) followed by E.coli (11, 10%), MRSA was found in 10 (9%) cases, streptococcus in 6 (5%) and pseudomonas in 5 (4%)cases. Polymicrobial infection was also seen in a few cases. Surgical intervention included superficialdebridement in 88 (77%) cases, toe amputation/forefoot amputation in 19 (17%) cases, and below/aboveknee (major) amputation in 7 (6%) cases. Commonest antibiotic used was Cefoperazone/Sulbactam in43 (38%) cases, alone or in combination, followed by Ceftraixone 36 (33%) cases. Linezolid was usedfor MRSA. Ninety-four (82%) patients responded to treatment and were recorded as ‘cured’.Conclusion: Diabetic Foot ulcers often present with serious foot infections. Commonest pathogens areStaph. aureus, E. coli, Pseudomonas spp. and MRSA. Treatment was effective withCefoperazone/Sulbactam and Ceftraixone. MRSA was treated successfully with Linezolid.Keywords: Diabetic foot, Diabetic foot infections (DFI), Staph. Aureus, E. coli, MRSA, antibiotics
Abbott CA, Carrington AL, Ashe H, Bath S, Every LC, Griffiths
J, et al. The north-west diabetes foot care study: incidence of, and
risk factor for, new diabetic foot ulceration in community-based
patient cohort. Diabet Med 2002;19:377–84.
Katsilambros N, Dounis E, Nicholas Tentolouris, Tsapogas P.
Atlas of the diabetic foot. Hoboken NJ: Jon Wiley & Sons Ltd;
International Diabetes Federation. Diabetes atlas. Executive
summary. 2nd ed. Belgium IDF; 2003.
Boulton AJ, Kirsner RS, Vileikyte L. Clinical practice:
neuropathic diabetic foot ulcers. N Engl J Med 2004;351:48–55.
Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in
patients with diabetes. JAMA 2005;293:217–28.
Levin ME. Classification of diabetic foot wounds. Diabetes Care
Reiber GE, Boyko EJ, Smith DG. Lower extremity foot ulcers and
amputations in diabetes. In: Diabetes in America, Vol 2.
Bethesda, MD: National Institutes of Health 1995.p. 409–27.
Ali SM, Basit A, Sheikh T, Mumtaz S, Hydrie MZ. Diabetic foot
ulcer-A prospective study. J Pak Med Assoc 2001;51:78–81.
Rooh UM, Ahmed M, Griffin S. Evaluation and management of
diabetic foot according to Wagner’s classification. A study of 100
cases. J Ayub Med Coll Abbottabad 2003;15(3):39–42.
Faizur Rehman, Nadir S. Diabetic Foot. J Postgrad Med Inst
Esposito S, Leone S, Noviello S, Foire M, Ianniello F, Felaco
FM, et al. Foot infections in diabetes (DFI) in the out-patient
setting: an italian multicentre observational survey. Diabet Med
World Health Organization Expert Committee. Definition,
diagnosis and classification of diabetes mellitus and its
complications. Report of a WHO consultation, part 1: Diagnosis
and Classification of Diabetes Mellitus. Geneva: World Health
Lipsky BA, Berendt AR, Deery HG, Embil JM, Joseph WS,
Karchmer AW. Diagnosis and treatment of diabetic foot
infections. Clin Infect Dis 2004;39:885–910.
Young MJ, Boulton AJ, Mac Leod AF, Williams DR, Sonksen
PH. A multicentre study of the prevalence of diabetic peripheral
neuropathy in the United Kingdom hospital clinic population.
Wagner FW Jr. The dysvascular foot: a system for diagnosis and
treatment. Foot Ankle 1981;2:64–122.
Zafar A. Management of diabetic foot: two years experience. J
Ayub Med Coll Abbottabad 2001;13(1):14–6.
Ali SM, Basit A, Fawwad A, Ahmedani MY, Miyan Z, Malik
RA. Presentation and outcome of diabetic foot at a tertiary care
unit. Pak J Med Sci 2008;24:651–6.
Levin ME. Classification of diabetic foot wounds. Diabetes Care
Lipsky BA, Sheehan P, Armstrong DG, Tice AD, Polis AB,
Abramson MA. Clinical predictors of treatment failure for
diabetic foot infections: data from a perspective trial. Int Wound J
Boulton A. Lawrence lecture. The diabetic foot: neuropathic in
aetiology? Diabet Med 1990;7:852–8.
J Ayub Med Coll Abbottabad 2011;23(1)
Lipsky BA, Armstrong DG, Citron DM, Tice AD, Morgenstern
DE, Abramson MA. Ertapenem versus piperacillin/ tazobactam
for diabetic foot infections (SIDESTEP): prospective,
randomised, controlled, double- blinded, multicentre trial, Lancet
Kaufman J, Breeding L, Rosenberg N. Anatomic location of
acute diabetic infection. Its influence on the outcome of
treatment. Am Surg 1987;53:109–112.
Vijay V, Snehalatha C, Ramachandran A. Sociocultural practice
that may affect the development of the diabetic foot. IDF Bull
Sapico FL, Witte JL, Canawati HN, Montgomerie JZ, Bessman
AN. The infected foot of the diabetic patient: quantitative
microbiology and analysis of clinical features. Rev Infec Dis
Ge Y, MacDonald D, Hait H, Lipsky BA, Zasloff M, Holroyd K,
Microbiological profile of infected diabetic foot ulcers. Diabet
Wheat LJ, Allen SD, Henry M, Kernek CB, Siders JA, Kuebler
T. Diabetic foot infections. Arch Intern Med 1986;146:1935–40.
Abdulrazak A, Bitar ZI, Al-Shamali AA, Mobasher LA.
Bacteriological study of diabetic foot infections. J Diabetes
Mantey I, Hill RL, Foster AV, Wilson S, Wade JJ, Edmonds ME.
Infection of foot ulcers with Staphylococcus aureus associated
with increase mortality in diabetic patients. Commun Dis Public
Dang CN, Prasad YD, Boulton AW, Jude EB. Methicillinresistant Staphylococcus aureus in the diabetic foot clinic: a
worsening problem. Diabet Med 2003;20:159–61.
Fluckiger U, Widmer AF. Epidemiology of methicillin-resistant
Staphylococcus aureus. Chemotherapy 1999;45:121–34.
Centers for Disease Control and Prevention. Vancomycinresistant Staphylococcus aureus-Pennsylvania, 2002. MMWR
Morb Mortal Wkly Rep 2002;51:902.
Rubinstein E, Cammarata SK, Oliphant TH, Wunderink RG.
Linezolid (PNU-100766) versus vancomycin in the treatment of
hospitalized patients with nosocomial pneumonia: a randomized,
double-blind, multicenter study. Linezolid Nosocomial
Pneumonia Study Group. Clin Infect Dis 2001;32:402–12.
Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B.
Linezolid versus vancomycin for the treatment of methicillinresistant Staphylococcus aureus infections. Linezolid MRSA
Study Group. Clin Infect Dis 2002;34:1481–90.
Lovering AM, Zhang J, Bannister GC, Lankester BJ, Brown JH,
Narendra G, et al. Penetration of linezolid into bone, fat, muscle
and haematoma of patients undergoing routine hip replacement. J
Antimicrob Chemother 2002;50:73–7.
Rana B, Butcher I, Grigoris P, Murnaghan C, Seaton RA, Tobin
CM. Linezolid penetration into osteo-articular tissues. J
Antimicrob Chemother 2002;50:747–50.
Oyibo SO, Jude EB, Tarawneh I, Nguyen HC, Harkless LB,
Boulton AJ. A Comparison of Two Diabetic Foot Ulcer
Classification Systems. Diabetes Care 2001;24:84–8.